drugset / Trial / NCT01728337

Phase IV Study On Muscle Activity Of Two Commercial Preparations Of Botulinum

NCT01728337

Phase 4 Completed 80 enrolled Hexsel Dermatology Clinic
RandomizedParallel-groupDouble-blindTreatment

Summary

this study was proposed to provide more scientific and objective data on the clinical and aesthetic effects of these two toxins (Dysport and Xeomin).

Timeline

Start
2011-07
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 12 iu
Comparator Botulinum toxin type A Protein / enzyme biologic 30 iu

Indications

No indication recorded.